Procuring vaccines for COVID-19

Public Services and Procurement Canada (PSPC) is working with the Public Health Agency of Canada (PHAC), Health Canada and Innovation, Science and Economic Development Canada to identify and procure potential vaccine candidates and supplies.

On this page

COVID-19 vaccine agreements

On behalf of PHAC, and based on advice from the COVID-19 Vaccine Task Force, PSPC is leading negotiations and finalizing agreements with suppliers of COVID-19 vaccine candidates.

To date, the Government of Canada has invested over $1 billion to secure access to promising vaccine candidates.

This includes up-front payments that companies require to support vaccine development, testing and at-risk manufacturing. Subsequent payments are contingent on vaccines passing clinical trials and obtaining regulatory approval.

These investments ensure Canada’s earliest possible access to the production of an approved COVID-19 vaccine.

All vaccine candidates will require Health Canada authorization prior to being used to vaccinate anyone in Canada.

Vaccine agreements with suppliers
Supplier Doses Authorized Anticipated delivery start
AstraZeneca 20 million AstraZeneca / COVISHIELD authorization March 2021
Verity Pharmaceuticals Canada Inc./Serum Institute of India (in collaboration with AstraZeneca Canada Inc.) 2 million AstraZeneca / COVISHIELD authorization March 2021
Moderna 44 million Moderna authorization December 2020
Pfizer Up to 76 million Pfizer authorization December 2020
Johnson & Johnson Table 1 Note * Up to 38 million Johnson & Johnson authorization April 2021
Medicago Up to 76 million No Pending Health Canada authorization
Novavax Up to 76 million No Pending Health Canada authorization
Sanofi and GlaxoSmithKline Up to 72 million No Pending Health Canada authorization

Table 1 Note

Table 1 Note *

All of the vaccine candidates for which Canada has agreements are a 2-dose vaccine, with the exception of the Johnson & Johnson candidate, which is currently expected to be a 1-dose vaccine.

Return to Table 1 Note * referrer

Future vaccine supply

The Government of Canada is securing access to safe and effective COVID-19 vaccines now and into the future. Canada has secured COVID-19 vaccines from Pfizer for 2022 and 2023, with options to extend into 2024.

In addition to providing booster vaccine doses, the agreement provides flexibility to procure Pfizer’s new COVID-19 vaccine adaptations, such as those to protect against mutations or variants of concern and vaccines developed for younger populations.

As part of the agreement with Pfizer:

These doses are in addition to the 48 million doses of Pfizer-BioNTech’s COVID-19 vaccine arriving before the end of September 2021 as part of Canada’s existing agreement.

COVID-19 Vaccine Global Access Facility

The Government of Canada is participating in the COVID-19 Vaccine Global Access (COVAX) Facility, a global procurement mechanism that will help develop and deliver safe, equitable and accessible COVID-19 vaccines. Participation in the COVAX Facility also provides Canadians potential access to 6 additional vaccine candidates.

The Government of Canada is committing approximately $220 million to the facility to procure up to 15 million vaccine doses for everyone in Canada. An additional $220 million will be channeled through the COVAX Advance Market Commitment to purchase doses for low and middle income countries, increasing their access to a safe and effective COVID-19 vaccine.

Vaccine-related supplies

The Government of Canada also continues to purchase the necessary supplies for the administration of different vaccines. Contracts are in place for personal protective equipment and ancillary supplies, such as:

We have put in place contracts for the supplies required to administer nearly 75 million doses of COVID-19 vaccines, including syringes, needles and gauze. To date, we have received enough supplies to administer more than 74 million doses.

Canada has ordered 282 million syringes of varying sizes to accommodate a range of requirements in the administration of vaccines. This includes 192 million 1 millilitre syringes of which 179.7 million are low-dead volume syringes and 10 million are ultra-low-dead volume syringes. Canada has also ordered 81 million low-dead volume needles.

End-to-end logistics

The Government of Canada has awarded a contract to FedEx Express Canada and Innomar Strategies Inc., for an end-to-end COVID-19 logistics solution for COVID-19 vaccines.

Government of Canada awards contract to distribute COVID-19 vaccine from coast to coast to coast

The contract will support the distribution of vaccines across Canada. Specifically, working under the direction of PHAC’s National Operations Centre, led by Major-General Dany Fortin, FedEx Express Canada and Innomar Strategies Inc. will provide a variety of services that will assist in warehousing and transportation to provincial and territorial authorities and Indigenous partners to support timely and efficient vaccine administration across the country.

Freezers and dry ice

Given the complexity of vaccine distribution, including the need to transport and store vaccines at specific temperatures, PSPC is also procuring other goods and services required to support the eventual distribution of a vaccine to everyone in Canada.

Freezers and refrigerators

The Government of Canada has now purchased 600 freezers and 100 refrigerators.

PSPC, on behalf of PHAC, has awarded contracts for the purchase of:

Dry ice

The Government of Canada has awarded standing offers for the national delivery of tens of thousands of kilograms of dry ice weekly, on an as-needed basis to 10 Canadian companies:

The provinces and territories are able to issue call-ups against these offers directly, to meet immediate needs without delay.

National vaccine management information technology platform

On behalf of PHAC, PSPC is contracting a service provider to build further functionality into PHAC’s current operational and well-developed surveillance and coverage information technology (IT) systems. This enhanced national vaccine management IT platform (NVMIP) will help manage vaccine rollout, administration and reporting on a go forward basis, as the volume of deliveries increases.

News

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: